Armata Pharmaceuticals, Inc.
ARMP
$2.51
$0.083.29%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -49.17% | -19.18% | 142.69% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -49.17% | -19.18% | 142.69% | -- |
| Cost of Revenue | -48.30% | -32.27% | 2.76% | 124.31% | -96.09% |
| Gross Profit | 719.81% | 29.96% | -3.83% | 145.14% | 95.56% |
| SG&A Expenses | -23.84% | 2.36% | 4.53% | -9.46% | 46.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.35% | -22.44% | 6.01% | 10.10% | 12.30% |
| Operating Income | 42.55% | 19.92% | -10.02% | 5.61% | -23.73% |
| Income Before Tax | -281.34% | 73.90% | 113.10% | 82.41% | 353.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -281.34% | 73.90% | 113.10% | 82.41% | 353.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -281.34% | 73.90% | 113.10% | 82.41% | 353.34% |
| EBIT | 42.55% | 19.92% | -10.02% | 5.61% | -23.73% |
| EBITDA | 44.15% | 21.16% | -9.40% | 6.64% | -23.38% |
| EPS Basic | -281.17% | 73.94% | 113.08% | 82.46% | 352.80% |
| Normalized Basic EPS | 26.90% | 2.31% | -24.60% | -7.70% | -49.97% |
| EPS Diluted | -81.97% | 71.51% | 4.67% | 82.46% | -45.96% |
| Normalized Diluted EPS | -17.79% | 40.58% | 23.71% | -7.70% | -45.99% |
| Average Basic Shares Outstanding | 0.11% | 0.17% | 0.23% | 0.26% | 0.24% |
| Average Diluted Shares Outstanding | -37.86% | 64.65% | 63.66% | 0.26% | 3.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |